News articles about Fluidigm Corporation (NASDAQ:FLDM) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fluidigm Corporation earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 44.5118037027986 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Levin Capital Strategies, L.P. Buys 4,227 Shares of Fluidigm Corporation (FLDM) Stock (americanbankingnews.com)
- Fluidigm Corporation (FLDM) to Release Earnings on Thursday (americanbankingnews.com)
- ETFs with exposure to Fluidigm Corp. : October 25, 2017 (finance.yahoo.com)
- Fluidigm Introduces Imaging Mass Cytometry System for Highly Multiplexed Protein Detection in Tissues (finance.yahoo.com)
- Fluidigm Announces Agreement With the University of Zurich to Distribute histoCAT for Multiparameter Imaging Mass Cytometry Data Analysis (finance.yahoo.com)
Separately, ValuEngine raised shares of Fluidigm Corporation from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd.
Shares of Fluidigm Corporation (NASDAQ:FLDM) traded up 0.52% during mid-day trading on Tuesday, hitting $5.80. 221,189 shares of the stock traded hands. The stock has a 50 day moving average price of $5.10 and a 200-day moving average price of $4.52. The company’s market cap is $170.60 million. Fluidigm Corporation has a one year low of $2.52 and a one year high of $8.69.
Fluidigm Corporation (NASDAQ:FLDM) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.02. The firm had revenue of $23.90 million for the quarter, compared to analyst estimates of $23.50 million. Fluidigm Corporation had a negative return on equity of 121.04% and a negative net margin of 74.05%. Fluidigm Corporation’s revenue for the quarter was down 15.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.63) EPS. On average, analysts forecast that Fluidigm Corporation will post ($1.95) earnings per share for the current fiscal year.
In other Fluidigm Corporation news, insider Levin Capital Strategies, L.P. bought 22,363 shares of the business’s stock in a transaction on Monday, October 23rd. The shares were bought at an average cost of $5.47 per share, with a total value of $122,325.61. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Stephen Christopher Linthwaite bought 45,000 shares of the business’s stock in a transaction on Tuesday, August 8th. The stock was acquired at an average cost of $2.66 per share, for a total transaction of $119,700.00. Following the completion of the transaction, the chief executive officer now owns 106,977 shares in the company, valued at $284,558.82. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,542,671 shares of company stock worth $15,558,699 over the last three months. 4.70% of the stock is currently owned by corporate insiders.
About Fluidigm Corporation
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
What are top analysts saying about Fluidigm Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fluidigm Corporation and related companies.